Many people with multiple sclerosis (MS) have a type of sclerosis called relapsing-remitting multiple sclerosis (RRMS). It mostly affects when around 20 years to 30 years old. People affected with RRMS have attacks whenever their symptoms get severe and these attacks are called as relapses. Sometimes when an attack occurs after recovery when there are no traces of symptoms and they are called remission. This disease usually worsens as time progresses.
Clinical trials are conducted in medical research labs to find better ways to prevent and treat diseases or diagnose them. They give solutions to the medical approaches suitable for certain illness to a certain group of people specifically. These trials help a great deal in making healthcare decisions. Since they answer scientific questions, these trials are required to be carried on under strict and scientific standards that protect the interests of the patients. They are also the final and the most important stage of clinical research and development. Clinical trials for drugs take place in four phases- first, they test an experimental drug on a few people and study the effects; second, they test the drug on more people than in Phase 1 which may extend up to years; third, they include many other participants to test for safety and efficacy and study the side effects deeper than in Phase 2; fourth, getting approval of the usage of drug from the relevant authority.
Ken Research’s Relapsing Multiple Sclerosis (RMS) Global Clinical Trials Review, H1, 2018 gives an overview of the global clinical trials landscape and top-level data related to clinical trials by Region, Country (G7 and E7), Trial Status, trial Phase, Sponsor type, and Endpoint status. The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company and all the unaccomplished trials (Terminated, Suspended and Withdrawn) with the reason for their non-accomplishments. It provides enrolment trends for the past five years and the latest news relating to these trials for the past three months. The companies involved in the clinical trials of relapsing multiple sclerosis are Biogen Inc, Sanofi, E. Merck KG, Novartis AG, F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Ltd, Celgene Corp, Pharmaceutical Product Development LLC, Perrigo Company Plc and Johnson & Johnson. The report will enhance the decision- making capabilities and helps to create an effective counter-strategy to gain a competitive advantage.
To know more, click on the link below:
https://www.kenresearch.com/healthcare/pharmaceuticals/relapsing-multiple-sclerosis/154895-91.html
Related Reports:
Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
+91-9015378249
